Burning Rock Biotech Product Used in Phase 3 AstraZeneca-Sponsored Clinical Trial
Burning Rock Biotech Limited’s (Nasdaq: BNR) comprehensive genomic profiling product, OncoScreenTM Plus, has been featured in a Phase 3 multi-regional clinical trial in support of advancement in breast cancer treatment.
OncoScreenTM Plus was used in the AstraZeneca (Nasdaq: AZN) trial to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients enrolled in China.
Highlights
The study, CAPItello-291, assessed the safety and efficacy of Capivasertib–fulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy.
The study demonstrated that Capivasertib–fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.
Burning Rock stated it was proud to have supported AstraZeneca in this high impact study, following a rigorous test solution provider evaluation process.
About Burning Rock
Burning Rock Biotech Limited focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
